Cancer Res:癌症药物筛选新策略

2018-11-05 小通 生物通

研究人员设计了一种筛选潜在药物的新方法,筛选那些能通过两种途径干扰肿瘤细胞的药物。他们的研究试图建立在现有方法的基础上,该方法能鉴定靶向癌细胞中一种重要蛋白质的药物,即端粒酶的药物。

一种鉴定潜在癌症药物的新方法可以简化治疗。

研究人员设计了一种筛选潜在药物的新方法,筛选那些能通过两种途径干扰肿瘤细胞的药物。他们的研究试图建立在现有方法的基础上,该方法能鉴定靶向癌细胞中一种重要蛋白质的药物,即端粒酶的药物。

科学家们希望找到一种药物,这种药物不仅可以抑制这种蛋白质,而且在癌细胞分裂其染色体以形成新细胞时也会引起错误。这两个方面的攻击可以防止癌细胞生长,从而杀死肿瘤。

来自爱丁堡大学、巴黎居里研究所、美国国立癌症研究所和日本卡萨萨DNA研究所的研究人员,使用人工荧光标记的人工人类染色体测试药物。这使得团队能够容易地检测药物治疗导致染色体丢失的时间和频率。

以这种方式鉴定的药物随后在不同类型的癌细胞中进行测试,以确切地了解它们如何能够以高速率破坏染色体分裂。



研究人员希望这些新发现的药物能促进更有效的治疗方法发展。这项研究发表在Cancer Research上,得到了惠康、美国国立卫生研究院和日本政府的支持。

参与这项研究的爱丁堡大学生物科学学院的William C Earnshaw教授说:“我们的方法能够选择药物破坏癌细胞的正常分裂。我们的希望是,这将导致更有效的肿瘤靶向治疗方法的发展。”

参与这项研究的爱丁堡大学生物科学学院的Mar Carmena博士说:“我们希望在获得新的更有效的药物来靶向一系列的癌症方面,我们的双管齐下的方法是有用的。”

原始出处:Lee HS, Carmena M, Liskovykh M, et al. Systematic Analysis of Compounds Specifically Targeting Telomeres and Telomerase for Clinical Implications in Cancer Therapy. Cancer Res. 2018 Nov 1;78(21):6282-6296. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1679342, encodeId=44af16e934232, content=<a href='/topic/show?id=59f58e834a0' target=_blank style='color:#2F92EE;'>#药物筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87834, encryptionId=59f58e834a0, topicName=药物筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37927754929, createdName=hunizi014, createdTime=Sun Jan 20 04:49:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478426, encodeId=9f3314e8426cc, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569987, encodeId=3176156998e02, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584411, encodeId=3e5a15844111c, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351690, encodeId=aa4c35169010, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Nov 06 08:15:14 CST 2018, time=2018-11-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1679342, encodeId=44af16e934232, content=<a href='/topic/show?id=59f58e834a0' target=_blank style='color:#2F92EE;'>#药物筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87834, encryptionId=59f58e834a0, topicName=药物筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37927754929, createdName=hunizi014, createdTime=Sun Jan 20 04:49:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478426, encodeId=9f3314e8426cc, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569987, encodeId=3176156998e02, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584411, encodeId=3e5a15844111c, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351690, encodeId=aa4c35169010, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Nov 06 08:15:14 CST 2018, time=2018-11-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1679342, encodeId=44af16e934232, content=<a href='/topic/show?id=59f58e834a0' target=_blank style='color:#2F92EE;'>#药物筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87834, encryptionId=59f58e834a0, topicName=药物筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37927754929, createdName=hunizi014, createdTime=Sun Jan 20 04:49:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478426, encodeId=9f3314e8426cc, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569987, encodeId=3176156998e02, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584411, encodeId=3e5a15844111c, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351690, encodeId=aa4c35169010, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Nov 06 08:15:14 CST 2018, time=2018-11-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1679342, encodeId=44af16e934232, content=<a href='/topic/show?id=59f58e834a0' target=_blank style='color:#2F92EE;'>#药物筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87834, encryptionId=59f58e834a0, topicName=药物筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37927754929, createdName=hunizi014, createdTime=Sun Jan 20 04:49:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478426, encodeId=9f3314e8426cc, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569987, encodeId=3176156998e02, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584411, encodeId=3e5a15844111c, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351690, encodeId=aa4c35169010, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Nov 06 08:15:14 CST 2018, time=2018-11-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1679342, encodeId=44af16e934232, content=<a href='/topic/show?id=59f58e834a0' target=_blank style='color:#2F92EE;'>#药物筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87834, encryptionId=59f58e834a0, topicName=药物筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37927754929, createdName=hunizi014, createdTime=Sun Jan 20 04:49:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478426, encodeId=9f3314e8426cc, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569987, encodeId=3176156998e02, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584411, encodeId=3e5a15844111c, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Nov 07 13:49:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351690, encodeId=aa4c35169010, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Nov 06 08:15:14 CST 2018, time=2018-11-06, status=1, ipAttribution=)]
    2018-11-06 kafei

    学习了谢谢

    0

相关资讯

盘点:肥胖近期重要研究一览

【1】JAMA Oncol:女性肥胖与结直肠癌风险增加93%有关 来自华盛顿大学医学院的Yin Cao学者及其同事对85256名年龄在25岁-44岁之间的女性进行了22年的随访,探究体质指数(BMI)和结直肠癌风险之间的关系。结果发现,对于50岁以下的中青年群体,BMI≥30与结直肠癌风险增加93%有关!BMI每增加5个单位,与结直肠癌风险增加20%有关! 在这项研究中,研究人员使

2018年全球癌症免疫疗法研发趋势

2011年,ipilimumab治疗黑色素瘤适应症的批准标志着癌症免疫治疗(immuno-oncology)革命的开端,并且在近年来逐渐改变了癌症治疗的模式。自此之后,又有11个癌症免疫疗法被批准,很快成为多种癌症的标准疗法。为了解癌症免疫疗法的快速进展,2017年Cancer Research Institute发表了癌症免疫疗法的概况。近日,CRI的Jun Tang等学者在《Nature

干细胞的命运:与癌症息息相关

在过去的几十年里,癌症基本上被视为一种异常增殖和与生存息息相关的疾病,到目前为止,最常用的治疗方式是药物化疗和放射治疗。尽管这些疗法取得了成功,包括治愈像儿童急性淋巴细胞白血病和淋巴瘤,同样很明显的是,这些方法再面对有些癌症的时候具有一定的局限性。我们在促进癌症增长的信号和这些信号是如何被靶向的方面取得很大的进展,但有效控制癌症仍然是一个关键的科学和医学挑战。癌症的耐药性和复发性通常是因为癌症内部

上海癌协发布:7种高发癌症的早筛和预防指南(珍藏版)

对于癌症,早预防、早发现、早治疗是关键!上海市抗癌协会发布《居民常见恶性肿瘤筛查和预防推荐》,给出了针对肺、大肠、肝、胃、乳腺、宫颈、前列腺等7个器官常见恶性肿瘤的筛查和预防方法

癌症生物医药“缺芯”之痛:“用别人的枪打别人的靶”

当IC行业“缺芯”之痛触动国人的时候,一场生物医药产业的“芯片”竞争已悄然开始。自主创新能力不足一直是我国生物医药产业的发展之痛。痛点之一,是有生物医药产业“原始芯片”之称的细胞模型。细胞模型是生物医学基础研究和药物研发的核心要素与战略性源头资源,决定着生物医药产业的原始创新能力。我国细胞模型一直受制于人,成为制约我国生物医药产业的“卡脖子”环节。《了望》新闻周刊记者近日从中科院合肥物质科学

Nature Biomedical Engineering:首创抗癌新技术!华人科学家顾臻发新成果,治愈近90%癌症小鼠

华人科学家顾臻教授长期致力于智能递药体系的创新研发,已先后开发出包括“智能胰岛素贴片”、“癌症免疫疗法贴片”、“减肥贴片”在内的多项新技术!近日,其团队再发新成果,首次提出了一种“细胞联合递药”技术!动物试验表明,该技术可将抗癌药PD-1抗体成功运送至骨髓处,提升药效,并显着抑制病情复发。